Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer

IUBMB Life

Volumn 59, Issue 6, 2007, Pages 394-401

  Swellam, Menha ^a   Arab, Lobna R Ezz El ^b   Bushnak, Hussein A ^b  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Breast cancer; Diagnostic markers; HER 2 neu; MMP 2; Prognostic factors; TIMP 2

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GELATINASE A; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER GRADING; CANCER RELAPSE; CANCER STAGING; CELL LYSATE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOSOLIC FRACTION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY DIAGNOSIS; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PROGNOSIS; PROTEIN DEGRADATION; RECEIVER OPERATING CHARACTERISTIC; UNIVARIATE ANALYSIS;

ADULT; BIOLOGICAL MARKERS; BREAST NEOPLASMS; FEMALE; HUMANS; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 34347374045     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1080/15216540701395074     Document Type: Article

References (32)

1. Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., and Thun, M. J. (2004) Cancer statistics CA Cancer. J. Clin. 54, 8-29.
2. Duffy, M. K., Maguire, T. M., Hill, A., McDermott, E., and Ohiggins, N. (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2, 252-257.
3. Egeblad, M., and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
4. Stamenkovic, I. (2000) Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 10, 415-433.
5. Talvensaari-Mattila, A., Paakko, P., Blanco-Sequeiros, G., and Turpeenniemi-Hujanen, T. (2001) Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node positive breast carcinoma treated with antiestrogen adjuvant therapy. Br. Cancer Res. Treat. 65, 55-61.
6. Hoekstra, R., Eskens, F. A. L. M., and Verweij, J. (2001) Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 6, 415-427.
7. Felding-Habermann, B. (2003) Targeting tumor cell-platelet interaction in breast cancer metastasis. Pathophysiol. Haemost. Thromb. 33, 56-58.
8. Nakopoulou, L., Katsarou, S., Giannopoulou, L., Alexandrou, P., Tsirmpa, L., Panayotopoulou, E., Mavrommatis, J., and Keramopoulos, A. (2002) Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer. Mod. Pathol. 15, 26-34.
9. Wang, Z., Juttermann, R., and Soloway, P. D. (2000) TIMP-2 is required for efficient activation of proMMP-2 in vivo. J. Biol. Chem. 275, 26411-26415.
10. Zhou, Y., Yu, C., Miao, X., Tan, W., Liang, G., Xiong, P., Sun, T., and Lin, D. (2004) Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25, 399-404.
11. Sumita, G., Zoran, G., Amin, M., Al, R., and Gopalrao, V. N. V. (2004) FISH for HER-2/neu in breast cancer: standardization makes the difference. Ind. J. Cancer 41, 152-158.
12. Zadrozny, M., Smolarz, B., Makowaska, R., Kozlowska, E., and Kulig, A. (2002) Amplification of cerbB2 in female breast cancer. Exp. Oncol. 24, 198-202.
13. Huang, H. J., Neven, P., Drijkoningen, M., Paridaens, R., Wildiers, H., Van Limbergen, E., Berteloot, P., Amant, F., Vergote, I., and Christiaens, M. R. (2005) Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J. Clin. Pathol. 58, 611-616.
14. Gershenwald, J. E., Sumner, W., Calderone, T. et al. (2001) Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene 20, 3363-3375.
15. Rocca, G. L., Pucci-Minafra, I., Marrazzo, A., Taormina, P., and Minafra, S. (2004) Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br. J. Cancer 90, 1414-1421.
16. American Joint Committee of Cancer (AJCC) (1992) Manual for Staging of Cancer, 4th ed. Philadelphia, USA: J. B. Lippincott Co.
17. Robins, P., Pinder, S., and de-Klerk, N. (1995) Histological grading of breast carcinomas: a study of interobserved agreement. Hum. Pathol. 28, 873-879.
18. Eissa, S., and Seada, L. S. (1998) Quantitation of Bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with western blot and immunohistochemistry. Clin. Chem. 44, 1423-1429.
19. Bradford, M. M. (1976) Rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 722, 248-254.
20. Hawkes, R. (1986) The dot immunoinding assay. Methods Enzymol. 121, 484-491.
21. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning, 3rd ed. Cold Spring Harbor: Laboratory, New York, 18, 42-59.
22. Hanemaaijer, R., Verheijen, J. H., Maguire, T. M., Visser, H., Toet, K., McDermott, E., O'Higgins, N., and Duffy, M. J. (2000) Increased gelatinase-A and gelatinase-B activities in malignant vs benign breast tumors. Int. J. Cancer 86, 204-207.
23. Liu, S. C., Yang, S. F., Yeh, K. T., Yeh, C. M., Chiou, H. L., Lee, C. Y., Chou, M. C., and Hsieh, Y. S. (2006) Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Int. J. Cancer 366, 243-248.
24. Giannelli, G., Erriquez, R., Fransvea, E., Daniele, A., Trerotoli, P., Schittulli, F., Grano, M., Quaranta, M., and Antonaci, S. (2004) Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int. J. Cancer 109, 782-785.
25. Hoekstra, R., Eskens, F. A. L. M., and Verweij, J. (2001) Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 6, 415-427.
26. Mrozkowiak, A., Olszewski, W. P., Piascik, A., and Olszewski, W. T. (2004) HER2 status in breast cancer determined by IHC and FISH: comparison of the results. Pol. J. Pathol. 55, 165-171.
27. Hlupic, L., Jakic-Razumovic, J., Bozjikov, J., Coric, M., Belev, B., and Vrbanec, D. (2004) Prognostic value of different factors in breast carcinoma. Tumori 90, 112-119.
28. Tetu, B., Brisson, J., Wang, J. C., Lapointe, H., Beaudry, G., Blanchette, C., and Trudel, D. (2006) The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res. 8, 825-830.
29. Pellikainen, J. M., Ropponen, K. M., Kataja, V. V., Kellokoski, J. K., Eskelinen, M. J., and Kosma, V-M. (2004) Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to Activator Protein-2, HER2, and prognosis. Clin. Cancer Res. 10, 7621-7628.
30. Hsu, M. C., Chang, H. C., and Hung, W. C. (2006) HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion. J. Biol. Chem. 281, 4718-4725.
31. Schondorf, T., Hoopmann, M., Warm, M., Neumann, R., Thomas, A., Gohring, U-J., Crasten, E., and Mallmann, P. (2002) Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab. Clin. Chem. 48, 1360-1362.
32. Mannello, F. (2006) Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon? Recent Patent Anti-Cancer Drug Discov. 1, 91-103.